Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, October 8, 2026 – Life Biosciences (“Life Bio”), ...
BOSTON, October 1, 2026 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the company will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results